EDN1 and ischemia: Similar to HINT2 overexpression, Ru360 treatment alleviated the no-reflow phenomenon and maintained microvascular perfusion in ischemia hearts, as evidenced by increased thioflavin S perfusion, more FITC-perfused microvessels, enhanced eNOS phosphorylation, suppressed ET-1 expression, and higher nitrite content (Fig. 7a–d).